GlassScriptPhysician profile
Casey Ross Ward
NPI 1174063382
$1,859.73
in general payments reported to CMS, 2019-2025
19 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $405 · 2022: $803 · 2023: $486 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $603 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $603.10 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $365.88 | 2021-2025 | |
| Gilead Sciences, INC. | $299.92 | 2021-2023 | Epclusa |
| Indivior INC. | $221.08 | 2021-2023 | Sublocade |
| Alkermes, INC. | $199.36 | 2021-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $191.72 | 2022-2023 | |
| Lilly USA, LLC | $185.53 | 2021-2023 | Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals LP | $124.99 | 2021 | |
| Janssen Pharmaceuticals, INC | $36.83 | 2022-2023 | Invega Sustenna |
| Neurocrine Biosciences, INC. | $36.61 | 2023-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $34.58 | 2023-2025 | Austedo Xr, Austedo |
| Corium, LLC | $21.42 | 2025 | Azstarys |
| Lundbeck LLC | $21.04 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $20.34 | 2023 | Rexulti, Abilify Maintena |
| Exact Sciences Corporation | $19.16 | 2023 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $17.96 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $17.85 | 2023 | Proclaim |
| Boston Scientific Corporation | $17.20 | 2022 | |
| Noven Therapeutics, LLC | $15.37 | 2023 | Secuado |
| Novo Nordisk INC | $12.89 | 2023 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.